Smart Probio

Smart Probio is a South Korean biotechnology company specializing in the development of next-generation microbiome-based therapeutics, specifically live biotherapeutic products (LBPs). The company leverages a proprietary discovery platform to identify and optimize functional probiotic strains that modulate host metabolic and inflammatory pathways. Their primary research focus includes high-prevalence conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). By bridging the gap between traditional probiotics and pharmaceutical drugs, Smart Probio aims to provide safer and more sustainable treatment options for chronic diseases. The company is currently advancing its lead candidates through pre-clinical validation and formulation optimization.